Listed by the USPTO as NESTOR, DONNA MICHELLE
Tech Center 1600 • Art Units: 1621 1622 1626 1627 1629
This examiner grants 57% of resolved cases
Donna Michelle Nestor is an examiner in Tech Center 1600 with 83 resolved cases. The examiner maintains an allowance rate of 56.6 percent in Art Unit 1621. This rate applies to a diverse group of companies, including Hoffmann-La Roche Inc. and Remix Therapeutics Inc., indicating the frequency of grants within this portfolio.
A notable metric is the interview lift of 44.2 percent. This figure suggests that interviews are associated with a significant increase in the probability of allowance compared to the 56.6 percent baseline. For firms like GOODWIN PROCTER LLP and LANDO & ANASTASI, LLP, requesting an interview may be a highly effective strategy to resolve outstanding rejections and clarify technical nuances.
The median days to allowance is 1161. This duration provides a benchmark for applicants like Novartis AG and MARSHALL, GERSTEIN & BORUN LLP when planning their prosecution strategy. Given the 44.2 percent lift associated with interviews, practitioners might use verbal communication to potentially move cases toward a resolution. The data from the 83 resolved cases suggests that direct engagement is a key factor in successful outcomes.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18665776 | SYNTHESIS OF 2'-(7,7-dimethyl-1'H,7H-spiro[furo[3,4-b]pyridine-5,4'-piperidin]-1'-yl)-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one | Non-Final OA | Hoffmann-La Roche Inc. |
| 18479596 | PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS | Final Rejection | Hoffmann-La Roche Inc. |
| 18982128 | TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YLMETHYL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE | Non-Final OA | NOVARTIS AG |
| 17623060 | COMPOSITIONS AND METHODS OF TREATING LIVER CANCERS | Final Rejection | The Johns Hopkins University |
| 18294191 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18577851 | CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF | Final Rejection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17995806 | PI3 KINASE INHIBITORS AND USES THEREOF | Non-Final OA | Purdue Research Foundation |
| 18262053 | ARTEMISININ-PROTEASOME INHIBITOR CONJUGATES AND THEIR USE IN THE TREATMENT OF DISEASE | Final Rejection | CORNELL UNIVERSITY |
| 18548716 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | Final Rejection | KYOTO UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy56.6% of resolved applications examined by Donna Michelle Nestor were allowed (83 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is +44.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Donna Michelle Nestor took 1,161 days on average from filing to allowance.
Donna Michelle Nestor examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
